Prialt

(Ziconotide)

ApprovedPeptide

TTerezinha de Jesus Esteves Barata

Prialt is one of 23 small molecule programs targeting Cancer Pain. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Cancer PainActive, not recruiting

MyelopathyWithdrawn

Cancer PainPreclinical

Active, not recruiting

MyelopathyApproved

Withdrawn

Competition

Competitive Landscape

27 competitors in Cancer Pain

#DrugCompanyPhaseTrials

Duragesic

CCephalon

Approved

12 2

Oxycontin

PProtega

Approved

10 3

MS Contin

HHikma Pharmaceuticals LLC

Approved

8 4

Dilaudid

RRhodes Pharmaceuticals, L.P.

Approved

5 5

Epidiolex

Marinol

Suboxone

3 8

Tylenol

KKenvue Brands

Approved

2 9

Spravato

Advil

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Recruiting

Study completion

NCT04321408

Q4 2029

Recruiting

Cancer Pain

NCT06541184

Clinical

Trials by Indication[1]

Effectiveness1 trial

Ziconotide Effectiveness and Safety Trial in Patients With Chronic Severe Pain

Completed·EElan Pharmaceuticals·Phase 3·NCT00076544·300 enrolled

Myelopathy1 trial

Single Shot Intrathecal Ziconotide for Painful Neuropathy or Myelopathy

Withdrawn·AAaron Boster·Phase 4·NCT01992562

Cancer Pain1 trial

Ziconotide for Non-cancer Pain by Intrathecal Administration

Recruiting·EESTEVE Pharmaceuticals SAS··NCT06541184·85 enrolled

GIST1 trial

Patient Registry of Intrathecal Ziconotide Management(PRIZM)

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals··NCT01888120·93 enrolled

Chronic pain1 trial

A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain

Completed·NNeurex·Phase 2·NCT00002160·100 enrolled

2 more indications

Neuropathic Pain1 trial

Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer

Unknown status·NNational Cancer Institute, Naples·Phase 2·NCT00996983·16 enrolled

Unspecified2 trials

Intrathecal Bolus Doses of Ziconotide

Completed·UUniversity Hospital, Linkoeping·Phase 4·NCT01373983·26 enrolled

OP2C : Prialt® Observatory in Clinical Practice

Recruiting·IInstitut Cancerologie de l'Ouest··NCT04321408·300 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 28, 2004

PRIALT

NDA NDA021060

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Ziconotide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ziconotide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ziconotide. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021060). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Terezinha de Jesus Esteves Barata company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Approved[1]
Company: TTerezinha de Jesus Esteves Barata

Prialt

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2029

Trials by Indication[1]

Effectiveness1 trial

Myelopathy1 trial

Cancer Pain1 trial

GIST1 trial

Chronic pain1 trial

Neuropathic Pain1 trial

Unspecified2 trials

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News